Human/Mouse HMGA2 Antibody

Detection of Canine HMGA2 by Immunocytochemistry/Immunofluorescence

Immunocytochemical staining.A: Native CT1258 cells, B: CT1258-EGFP cells, C: CT1258-EGFP-HMGA2 cells. Approximately 50% of the native CT1258 cell line and of CT1258-EGFP cells showed a HMGA2-positive nuclear labelling. In approximately 70–80% of CT1258-EGFP-HMGA2 cells, a strong and exclusively nuclear labelling for HMGA2 was detectable. Image collected and cropped by CiteAb from the following publication (https://pubmed.ncbi.nlm.nih.gov/24914948), licensed under a CC-BY license. Not internally tested by R&D Systems.

Detection of Human HMGA2 by Western Blot

Nuclear Src activation and association with HMGA2 and SMYD3 gene promoters are observed in patient samples of PDACA Immunohistochemistry of human PDAC tumor samples. Human PDAC slides were immunostained for pY416Src (i) and (ii, left panels), HMGA2 (ii, middle panels), or SMYD3 (ii, right panels). Images were acquired at high (40X) magnification for pSrc (i), or low magnification (10X) of the same tumors for pSrc, HMGA2, or SMYD3 (ii). B. Pathology tissue-Chip (PAT-ChIP) of human PDAC samples derived from banked formalin-fixed paraffin-embedded tissues. Samples were subjected to chromatin immunoprecipitation assay using anti-Src antibody or IgG as control and amplified by PCR using specific primers for the HMGA2 (i) and SMYD3 (ii) promoters. Correct PCR product size is verified by DNA ladder. Image collected and cropped by CiteAb from the following publication (https://www.oncotarget.com/lookup/doi/10.18632/oncotarget.6635), licensed under a CC-BY license. Not internally tested by R&D Systems.

Detection of Human HMGA2 by Western Blot

Nuclear Src and p300 associate with HMGA2 and SMYD3 gene promoters and regulate their expression in PDAC and MEF cellsA and B. Chromatin-immunoprecipitation (ChIP) and quantitative polymerase-chain reaction (qPCR) analyses of Src-associated genes in Panc-1 cells and the effects of dasatinib. (A) Untreated Panc-1 cells were subjected to ChIP analysis using anti–Src antibody and qPCR to quantify the immune-complex-associated ACTB, HMGA2, or SMYD3 promoters. Pre-immune IgG was used as control. (B) Panc-1 cells were treated for three hours with 100 nmol/L dasatinib or untreated (DMSO) and subjected to ChIP using anti-Src (i), anti-p300 (ii), or control IgG antibodies as indicated. Antibody-associated eluates were analyzed by qPCR using primers spanning the promoter regions of the indicated genes. PCR signals were normalized to individual sample inputs and compared to IgG control and plotted as enrichment vs IgG. C. Analysis of HMGA2 and SMYD3 expression in Panc-1 cells. Panc-1 cells were treated with 100 nmol/L dasatinib, 20 μmol/L C646, or 0.01% DMSO (control) for the indicated times. Total RNA was extracted from cells for mRNA expression analysis (i), or whole-cell lysates were prepared for immunoblotting analysis of HMGA2 or SMYD3 expression (ii). D. Promoter enrichment as detected by ChIP-qPCR of Src at the mouse HMGA2 promoter in the SYF+/+ and SYF-Src cell lines. PCR reactions were performed using specific primers for the mouse HMGA2 promoter region analogous to the Src-associated region in the human HMGA2 promoter. Data are normalized to individual inputs and are expressed as enrichment vs IgG. All qPCR data represent mean ±SEM of three independent experiments. E. Immunoprobes of Src, pSrc, HMGA2 or GAPDH from whole-cell lysates prepared from SYF+/+ and SYF-Src cells treated with 100 nmol/L dasatinib or 20 μmol/L C646 for 24 hours. Control (−) lanes represent cells treated with 0.05% DMSO. Data are representative of three independent experiments. Image collected and cropped by CiteAb from the following publication (https://www.oncotarget.com/lookup/doi/10.18632/oncotarget.6635), licensed under a CC-BY license. Not internally tested by R&D Systems.

Detection of Human HMGA2 by Immunocytochemistry/Immunofluorescence

Immunocytochemical staining.A: Native CT1258 cells, B: CT1258-EGFP cells, C: CT1258-EGFP-HMGA2 cells. Approximately 50% of the native CT1258 cell line and of CT1258-EGFP cells showed a HMGA2-positive nuclear labelling. In approximately 70–80% of CT1258-EGFP-HMGA2 cells, a strong and exclusively nuclear labelling for HMGA2 was detectable. Image collected and cropped by CiteAb from the following publication (https://pubmed.ncbi.nlm.nih.gov/24914948), licensed under a CC-BY license. Not internally tested by R&D Systems.

Detection of Canine HMGA2 by Immunocytochemistry/Immunofluorescence

HMGA2 immunohistochemistry in canine OSCC. Immunolabelling of a canine tumour grade II: overview (A), tumour centre (B) and invasive front (C). HMGA2 staining in the tumour centre (B) revealed approx. 25% tumour cells with nuclear immunolabelling while cells at the invasive front showed approx. 50% staining (C). Magnification: (A) 100x, (B) and (C) 200x. Image collected and cropped by CiteAb from the following publication (https://pubmed.ncbi.nlm.nih.gov/25245141), licensed under a CC-BY license. Not internally tested by R&D Systems.

Detection of Human HMGA2 by Immunocytochemistry/Immunofluorescence

HMGA2 immunohistochemistry in human OSCC. Immunolabelling of a human tumour: overview (A), tumour centre (B) and invasive front (C). In the tumour centre (B) lower numbers of tumour cells with nuclear immunolabelling are present when compared to the respective invasive front (C). The invasive front shows numerous tumour cells exhibiting intense nuclear immunolabelling of HMGA2. Magnification: (A) 50x, (B) and (C) 200x. Image collected and cropped by CiteAb from the following publication (https://pubmed.ncbi.nlm.nih.gov/25245141), licensed under a CC-BY license. Not internally tested by R&D Systems.

Detection of Canine HMGA2 by Immunocytochemistry/Immunofluorescence

HMGA2 immunohistochemistry in canine OSCC. Immunolabelling of a canine tumour grade II: overview (A), tumour centre (B) and invasive front (C). HMGA2 staining in the tumour centre (B) revealed approx. 25% tumour cells with nuclear immunolabelling while cells at the invasive front showed approx. 50% staining (C). Magnification: (A) 100x, (B) and (C) 200x. Image collected and cropped by CiteAb from the following publication (https://pubmed.ncbi.nlm.nih.gov/25245141), licensed under a CC-BY license. Not internally tested by R&D Systems.

Detection of Human HMGA2 by Immunocytochemistry/Immunofluorescence

HMGA2 immunohistochemistry in human OSCC. Immunolabelling of a human tumour: overview (A), tumour centre (B) and invasive front (C). In the tumour centre (B) lower numbers of tumour cells with nuclear immunolabelling are present when compared to the respective invasive front (C). The invasive front shows numerous tumour cells exhibiting intense nuclear immunolabelling of HMGA2. Magnification: (A) 50x, (B) and (C) 200x. Image collected and cropped by CiteAb from the following publication (https://pubmed.ncbi.nlm.nih.gov/25245141), licensed under a CC-BY license. Not internally tested by R&D Systems.

Detection of Canine HMGA2 by Immunocytochemistry/Immunofluorescence

HMGA2 immunohistochemistry in canine OSCC. Immunolabelling of a canine tumour grade II: overview (A), tumour centre (B) and invasive front (C). HMGA2 staining in the tumour centre (B) revealed approx. 25% tumour cells with nuclear immunolabelling while cells at the invasive front showed approx. 50% staining (C). Magnification: (A) 100x, (B) and (C) 200x. Image collected and cropped by CiteAb from the following publication (https://pubmed.ncbi.nlm.nih.gov/25245141), licensed under a CC-BY license. Not internally tested by R&D Systems.

Detection of Human HMGA2 by Immunocytochemistry/Immunofluorescence

HMGA2 immunohistochemistry in human OSCC. Immunolabelling of a human tumour: overview (A), tumour centre (B) and invasive front (C). In the tumour centre (B) lower numbers of tumour cells with nuclear immunolabelling are present when compared to the respective invasive front (C). The invasive front shows numerous tumour cells exhibiting intense nuclear immunolabelling of HMGA2. Magnification: (A) 50x, (B) and (C) 200x. Image collected and cropped by CiteAb from the following publication (https://pubmed.ncbi.nlm.nih.gov/25245141), licensed under a CC-BY license. Not internally tested by R&D Systems.

Detection of Canine HMGA2 by Immunocytochemistry/Immunofluorescence

Immunocytochemical staining.A: Native CT1258 cells, B: CT1258-EGFP cells, C: CT1258-EGFP-HMGA2 cells. Approximately 50% of the native CT1258 cell line and of CT1258-EGFP cells showed a HMGA2-positive nuclear labelling. In approximately 70–80% of CT1258-EGFP-HMGA2 cells, a strong and exclusively nuclear labelling for HMGA2 was detectable. Image collected and cropped by CiteAb from the following publication (https://pubmed.ncbi.nlm.nih.gov/24914948), licensed under a CC-BY license. Not internally tested by R&D Systems.